
Qualigen Therapeutics QLGN
Annual report 2025
added 03-30-2026
Qualigen Therapeutics Depreciation & Amortization 2011-2026 | QLGN
Annual Depreciation & Amortization Qualigen Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 4.5 K | 153 K | 113 K | 217 K | 6.09 K | 5.72 K | 5.72 K | 5.21 K | 1.94 K | 3.48 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 217 K | 1.94 K | 51.5 K |
Quarterly Depreciation & Amortization Qualigen Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 19 K | 58.7 K | - | 99.7 K | 24 K | 29.7 K | - | 82.4 K | 53.7 K | 27.5 K | - | 110 K | 60 K | 50.3 K | - | 17 K | 57.9 K | 1.36 K | - | 4.26 K | 2.79 K | 1.36 K | - | 1.3 K | 1.3 K | 1.31 K | - | 1.3 K | 1.3 K | 1.25 K | - | 400 | 300 | 303 | - | 3.18 K | 2.53 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 110 K | 300 | 25.5 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amgen
AMGN
|
5.17 B | $ 350.13 | 2.98 % | $ 188 B | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Amneal Pharmaceuticals
AMRX
|
57.3 M | $ 12.73 | 3.33 % | $ 3.99 B | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.48 | 8.82 % | $ 394 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 24.57 | 5.59 % | $ 3.13 B | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.68 | 4.28 % | $ 16.8 M | ||
|
Avid Bioservices
CDMO
|
11.1 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 3.05 | 0.66 % | $ 6.64 B | ||
|
Cabaletta Bio
CABA
|
1.65 M | $ 3.05 | -0.5 % | $ 306 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
Cerus Corporation
CERS
|
1.43 M | $ 1.93 | 4.62 % | $ 368 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Concert Pharmaceuticals
CNCE
|
1.48 M | - | - | $ 401 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
CTI BioPharma Corp.
CTIC
|
1.95 M | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
5 K | - | -4.36 % | $ 27 M | ||
|
Cellectar Biosciences
CLRB
|
214 K | $ 2.83 | 2.91 % | $ 7.38 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
2.1 M | - | - | $ 2.18 B | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Dynavax Technologies Corporation
DVAX
|
4.63 M | - | - | $ 2.02 B | ||
|
Coherus BioSciences
CHRS
|
1.3 M | $ 1.73 | 3.59 % | $ 203 M |